Leadership & Pay ·
SCYNEXIS appoints Steven K. Burke, M.D., to its Board of Directors
SCYXScynexis Inc
SCYNEXIS, Inc. appointed Steven K. Burke, M.D., to its Board of Directors effective September 18, 2026. Dr. Burke joins the Nominating and Corporate Governance Committee and receives an annual retainer of $45,000 plus committee fees. His compensation includes initial grants of 5,750 stock options at $4.46 per share and 5,750 restricted stock units, along with recurring annual equity awards. Dr. Burke brings over 30 years of biopharmaceutical experience, currently serving as Senior Vice President and Chief Medical Officer at Akebia Therapeutics, Inc., where he leads drug development for chronic kidney disease. SCYNEXIS is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases.